Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $4.29M (cash outflow) fell 35.7% year over year, behind the -17.8% change in trailing-twelve-month net income. Sequentially, it fell 81.3% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.
Context
- Net income amounted to 1238.5% of revenue in FY2025, down 1986.5 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$23.38M (-53.5%) for the fiscal year ending Dec 2026, a slowdown from the -17.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.29M-81.3% QoQ
- Last fiscal yearDec 2025
- -$50.22M-17.2% YoY
- LTMMar 2026
- -$47.84M-17.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -35.7% | -3.9% | +31.8 pp |
| 1 year | -17.2% | -53.5% | -36.2 pp |
| 3-year CAGR | -11.7% | -24.1% | -12.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (50.22M) USD
- Year-over-year change
- +17.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (50.22M) | +17.2% |
| FY2024 | 2024-12-31 | (60.66M) | -118.4% |
| FY2023 | 2023-12-31 | (27.78M) | +61.9% |
| FY2022 | 2022-12-31 | (72.9M) | -13.7% |
| FY2021 | 2021-12-31 | (64.1M) | — |
Net Income vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's LTM Mar 2026 net income of $47.84M is the 9th largest of the 10 companies compared; the peer median is $77.6M.
- Its year-over-year change of -17.8% is the 6th highest of 10, against a peer median of -11.4%.
- Net income amounts to 2454.6% of revenue for IMDX, versus a peer median of 327.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $282.61M | +66241.3% | +67.6% | 9554.2% | |
| LTM Mar 2026 | $123.33M | +55.2% | -13.9% | 356.9% | |
| LTM Mar 2026 | $103.8M | +0.5% | -6.4% | 297.8% | |
| LTM Mar 2026 | $77.8M | -39.1% | -4.8% | 465.3% | |
| LTM Mar 2026 | $77.6M | -45.6% | -39.9% | 138.9% | |
| LTM Mar 2026 | $77.22M | -24.4% | +9.1% | — | |
| LTM Mar 2026 | $68.36M | +31.7% | +2.6% | 3832.0% | |
| LTM Mar 2026 | $54.29M | -11.4% | +42.6% | 187.8% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $47.84M | -17.8% | -11.7% | 2454.6% |
| LTM Mar 2026 | $31.99M | -57.0% | +9.4% | 41.0% | |
| Peer median (excluding IMDX) | $77.6M | -11.4% | +2.6% | 327.3% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| Deferred Income Tax | (9.26M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.84M | 10.04M | 6.57M | 1.91M | 2.22M |
| Change in Working Capital | 149K | (1.94M) | (3.97M) | (1.32M) | 2.73M |
| Accounts Receivables | (1.23M) | (575K) | 109K | (1.13M) | 485K |
| Inventory | 0 | 0 | 0 | (410K) | (36K) |
| Accounts Payables | (1.35M) | 297K | (4.76M) | 967K | 2.65M |
| Other Working Capital | 2.73M | (1.66M) | 677K | (749K) | (368K) |
| Other Non-Cash Items | 26.22M | 14.01M | 174K | 37.79M | 20.9M |
| Operating Cash Flow | (35.94M) | (45.57M) | (23.33M) | (20.71M) | (22.18M) |
| Capital Expenditures | (2.25M) | (4.34M) | (281K) | (516K) | (3.19M) |
| Acquisitions (Net) | (11.71M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 367K | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1.02M) | 4K | 0 |
| Investing Cash Flow | (13.96M) | (4.34M) | (932K) | (512K) | (3.19M) |
| Debt Repayment | (1.53M) | (1.43M) | (117K) | (201K) | (510K) |
| Common Stock Issued | 77.99M | 32.84M | 13.85M | 27.81M | 28.66M |
| Common Stock Repurchased | (239K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.15M | (483K) | (427K) | (1.8M) | (74K) |
| Financing Cash Flow | 78.36M | 35.81M | 12.19M | 20.43M | 28.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 973K |
| Net Change in Cash | 28.46M | (14.1M) | (12.07M) | (796K) | 3.68M |
| Free Cash Flow | (38.19M) | (49.91M) | (23.61M) | (21.23M) | (25.37M) |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.